Abnormalities of antioxidant metabolism in a case of Friedreich's disease.

  title={Abnormalities of antioxidant metabolism in a case of Friedreich's disease.},
  author={W. Helveston and J. Cibula and R. Hurd and B. Uthman and B. Wilder},
  journal={Clinical neuropharmacology},
  volume={19 3},
We report a patient with Friedreich's disease (FD) who exhibited abnormalities of antioxidant metabolism, including decreased levels of glutathione peroxidase, glutathione reductase, and selenium, and an increased lipid peroxide index. These abnormalities became normal after treatment with N-acetylcysteine, selenium, and low-dose vitamin E therapy. Treatment was associated with a decreased rate of clinical decline. FD is a neurodegenerative disorder that may be related to disturbed antioxidant… Expand
Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia.
  • M. Fryer
  • Biology, Medicine
  • Medical hypotheses
  • 2002
The administration of selenium supplements should normalize the antioxidant activity of myocardial glutathione peroxidase and slow the progression of the life-shortening cardiomyopathy associated with Friedreich's ataxia. Expand
Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease?
It is hypothesized that treatment with a sulfur-containing antioxidant such as N-acetylcysteine may provide a new neuroprotective therapeutic strategy for Parkinson's disease. Expand
Vitamin E Status and Neurodegenerative Disease.
  • M. Fryer
  • Medicine
  • Nutritional neuroscience
  • 1998
Evidence for any beneficial effects of vitamin E upon the course of Friedreich's ataxia, tardive dyskinesia, amyotrophic lateral sclerosis (motor neurone disease), Parkinson's disease, Alzheimer's disease and Huntington's disease is examined. Expand
Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases.
The mechanisms of N-acetylcysteine action at the cellular level, and the possible usefulness of this antioxidant for the treatment of age-associated neurodegenerative diseases are reviewed. Expand
A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy.
A cellular assay system is developed that discriminates between fibroblasts from FRDA patients and unaffected donors on the basis of their sensitivity to pharmacological inhibition of de novo synthesis of glutathione, and demonstrates for the first time that small-molecule GPX mimetics have potential as a novel treatment strategy for Friedreich Ataxia. Expand
Antioxidants and Friedreich's ataxia
Liver biopsy was undertaken in seven of 21 patients receiving adjuvant tamoxifen with liver steatosis, and NASH was shown in six patients, even though a high proportion of NASH is associated with obesity, type 2 diabetes, or hyperlipidaemia. Expand
Topical Review : Friedreich's Ataxia
The current state of knowledge concerning genetics, pathophysiology, pathology, clinical course, differential diagnosis, genotype-phenotype correlation, and therapy of Friedreich's ataxia is presented. Expand
Application of N-Acetylcysteine in Neurological Disorders
A systematic review found that NAC treatment appears safe and tolerable with favorable evidence for the use of NAC in anticancer medicine-induced neuropathy and no recommendations could be made for most of the neurological disorders. Expand
Vitamin E as a protective antioxidant in progressive renal failure
The membrane antioxidant vitamin E (α‐tocopherol) is examined as a potential therapeutic intervention that may help to slow the rate of decline of kidney function in conditions of chronic renal failure and the uremic state. Expand
Impact of Vitamins and Minerals Enriched Flora in the Management of Calciphytoliths: A Special Focus on Vitamin E
Calciphytoliths (calcium oxalate calculi) have a great influence on human health and are a disease with a high likelihood of recurrence at a rate of more than 10% within a year. Plant flavonoids,Expand